Crocin induces autophagic cell death and inhibits cell invasion of cervical cancer SiHa cells through activation of PI3K/AKT.

BACKGROUND: Cervical cancer is a prevalent tumor mainly induced by Human Papilloma Virus (HPV). Autophagy was inactivated with HPV to promote cancer progression. Here we explored the effects of crocin on cervical cancer cells, mainly on autophagy and apoptosis.
METHODS: SiHa cells were treated with crocin, and proliferation, metastases, apoptosis and autophagy were measured using a CCK-8 assay, transwell migration assay, flow cytometry and immunofluorescence. Protein levels were measured using western blotting. The antitumor effects of crocin were validated in female BALB/c nude mice injected with SiHa cells.
RESULTS: The result showed that 2, 4, 8 and 16 mM of crocin significantly reduced the viability of SiHa cells within 24 h. Subsequently, 0, 1, 2 and 4 mM crocin concentrations were used in later experiments. Treatment with crocin reduced invasive cells, while increasing autophagic and apoptotic cells dose-dependently. The enhanced apoptosis and autophagy were partly validated by an increase in cleaved caspase-3/caspase-3, cleaved caspase-9/caspase9, LC3B II/I, Beclin1 and ATG7. AMPK and mTOR were inactivated with crocin treatment, while PI3K was activated. These results indicated that crocin might promote autophagy and apoptosis by inactivating AMPK and mTOR signaling. Tumor progression was inhibited in mice treated with 50 mg/kg/d of crocin, which was demonstrated by smaller tumor volumes, less VEGF expression, more intense caspase-3 staining and increased LC3B II/I in the tumor tissues.
CONCLUSIONS: Crocin inhibited the progression of cervical cancer in vitro and in vivo, possibly through inactivation of AMPK and mTOR, inhibition of proliferation and invasion, and promotion of autophagy and apoptosis. These results support the potential therapeutic value of crocin in treating cervical cancer. 2020 Annals of Translational Medicine. All rights reserved.

Introduction

Cervical cancer, the most common human papillomavirus (HPV)-associated cancer, is one of the most prevalent tumors among women in the developing world (1). As vaccination is still largely economically unavailable, cervical cancer continues to be a growing major public health issue (2). Once diagnosed, the prognosis of cervical cancer is poor, especially in women with metastatic or recurrent disease. Novel therapeutic approaches including immunotherapy and targeted therapy, for example platinum combined with bevacizumab or pembrolizumab, have been able to extend overall survival (3). However, these treatment approaches remain insufficient and expensive.

Autophagy have critical effects on HPV infection and development of cervical cancer [reviewed in (4)]. HPV inhibited autophagy via inhibiting the fusion of autophagosome-lysosome with multiple ways. Autophagy was inhibited upon infection to avoid digestion, and in later processes to promote proliferation and carcinogenesis of infected cells. Inhibited autophagy could also avoid apoptotic cell death induced with violent autophagy. It is thus very important to restore the autophagic processes in treating cervical cancer.

Saffron, a traditional Chinese medicine, is the dried dark-red stigma of the plant Crocus sativus L. Saffron has been used traditionally to treat some conditions (5), such as certain cancers, neurological defects, cognitive problems and inflammatory diseases. One of the main bioactive components of Saffron is crocin, a soluble carotenoid with two D-gentiobioside glycosyl esters. The mechanism of action of crocin is complex (5), and includes the inhibition of DNA and RNA synthesis, reversion of epithelial-mesenchymal transition (EMT), suppression of cell invasion and metastasis, targeting of cellular topoisomerase and microtubules, induction of apoptosis, suppression of telomerase activity, reduction of oxidative stress, and epigenetic effects. These mechanisms suggest that crocin may have potential as an antitumor agent. Furthermore, emerging evidence suggests that saffron is selectively toxic to tumor cells but safe to normal cells (6,7). Crocin was implied to induce autophagy and promote apoptosis in hepatocellular carcinoma by inhibiting Akt/mTOR activity (8). Crocin has also demonstrated time and dose dependent inhibition of cervical cancer cell viability, and induced apoptosis and cell cycle arrest (7). However, whether or not autophagy and apoptosis could be induced with crocin in cervical cancer still require further investigation.

To this end, the current study tested the effects of crocin on SiHa cells. Viability, apoptosis, autophagy and potential signaling molecules were investigated, and also validated in female BALB/c nude mice. We present the following article in accordance with the ARRIVE reporting checklist (available at http://dx.doi.org/10.21037/atm-20-5882).

Methods

Cell culture and viability

SiHa cells were purchased from the American Type Culture Collection (Rockville, MD, USA), and were maintained at 37 °C with 5% CO2. Cells were cultured with Dulbecco’s modified eagle medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin solution. For testing cell viability, the SiHa cells were seeded onto 96-well plates with 3×103 cells/well in 100 µL of DMEM medium supplemented with 0.06, 0.13, 0.25, 0.5, 1, 2, 4, 8 and 16 mM of crocin (#17304, Sigma-Aldrich, Missouri, USA). After 22 hours, 10 µL CCK-8 solution was dissolved in 90 µL of DMEM medium and subsequently added to each well. The plates were incubated for 2 hours, and the absorbance value was measured at 450 nm.

Transwell migration assay

A transwell migration assay was conducted to measure cell invasion. The Matrigel (Becton, Dickinson and Company, Bioscience, San Jose, CA, USA) was pre-cooled at 4 °C overnight for liquidation, and diluted with serum-free medium on ice for a 1:1 dilution. The Matrigel mixture (15 µL) was then added to the upper chamber (Costar, Cambridge, MA, USA) in each well and cultured at 37 °C for 1 hour, then rinsed three times using serum-free medium. SiHa cells (1×105 cells) suspended in DMEM were added to the upper chamber, and 600 µL DMEM complete medium containing 15% FBS was added to the basolateral chamber. To both chambers, 0, 1, 2 or 4 mM of crocin was added, then cultured for 24 hours. The chambers were then fixed with 50% methyl alcohol for 15 minutes. Crystal violet staining was performed, and 6 visual fields from each well were randomly observed and imaged under an inverted microscope (200×, Olympus Optical Co., Ltd.). The average number of cells was calculated in each field.

Flow cytometry

To detect cell apoptosis, SiHa cells were treated with crocin (0, 1, 2 and 4 mM) for 24 hours then digested with trypsin. The trypsin digested cells (1×106) were subjected to flow cytometry using an Annexin V-FITC/PI Apoptosis Detection kit (Beyotime, Shanghai, Chain) following the manufacturer’s protocol. Cells with Annexin V-positive values were considered early apoptotic cells, those with PI-positive values were considered necrotic, and those with double positive values were considered late apoptotic.

Western blotting analysis

Western blotting was performed to measure protein expression. SiHa cells were treated with crocin (0, 1, 2 and 4 mM) for 24 hours then washed twice with cold PBS, and RIPA lysis buffer (Beyotime) was added to collect protein lysates. Total protein concentration was measured using the BCA Protein Assay Reagent (Pierce, Rockford, IL, USA), and the sample concentrations were diluted with PBS. Equal amounts of protein from experimental groups were subjected to SDS-PAGE and transferred to PVDF membranes. The membranes were blocked with 5% fat-free milk, probed with the primary and secondary antibodies, then enhanced with a chemiluminescence (ECL) reagent (Amersham Pharmacia Biotech). The following antibodies (Abcam, Cambridge, UK) were used: anti-Caspase-3 (ab32351), anti-Caspase-9 (ab202068), anti-LC3B (ab48394), anti-Beclin1 (ab210498), anti-ATG-7 (ab52472), anti-AMPK (ab80039), anti-p-AMPK (ab133448), anti-AKT (ab8805), anti-p-AKT (phospho T308, ab38449), anti-mTOR (ab2732), anti-p-mTOR (ab109268), anti-VEGF (ab150375), anti-Actin (ab8227) and goat-anti-rabbit IgG (ab205718).

Immunofluorescence

Immunofluorescence of SiHa cells was performed as previously described (9). After fixation with 4% paraformaldehyde for 15 min at 37 °C, SiHa cells were permeabilized with 0.1% Triton X-100 (Beyotime, China) for 30 min, and blocked with goat serum for 15 min. Cells were incubated with primary LC3 antibody (1 µg/m, Abcam) overnight at 4 °C, and then with AlexaFluor® 647 conjugated secondary antibody (#4414, 1:2,000, CST, USA) at room temperature for 60 min. DAPI (Beyotime) was used to counterstain the cell nuclei. Immunofluorescence images were acquired with confocal microscopy (LSM 510 Meta, Zeiss, Oberkochen, Germany). LC3 puncta were counted from 10 random fields per slide.

Animal experiments

The study was approved by the Medical Ethics Committee of West China Second Hospital, Sichuan University (No. 2014-2020). All animal experiments were approved by the Institutional Animal Care and Use Committee of Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, and were performed according to institutional guidelines. Twelve 4-week-old female BALB/c nude mice were purchased from Shanghai SLAC Laboratory Animal Co., Ltd. The mice were housed in 2 polypropylene cages at room temperature with a relative humidity of 60 ± 5% and a photoperiod of 12 h/day. Approximately 1×107 SiHa cells suspended in 100 µL of PBS were injected into the right thigh of all mice. After 5 days, the formation of tumors was confirmed, and mice were randomly divided into two groups and administered as: crocin (50 mg/kg/d) or saline (vehicle) by referring to previous research (10). After 4 weeks, the mice were sacrificed. The tumors were surgically removed, fixed in 10% formalin, and subjected to routine histological examination.

Immunohistochemical staining

Caspase-3 and vascular endothelial growth factor (VEGF) protein expression in xenograft tumors was determined by immunohistochemistry (IHC) (11). The primary antibodies used were the same as those used for western blotting. The fixed tumors were embedded in paraffin and 4 µm slices were sectioned. The sections were rehydrated and incubated in citrate buffer for 3 min at 100 °C. The sections were then incubated with primary antibodies against caspase-3 and VEGF overnight at 4 °C. After further incubation with goat anti-rabbit IgG (Boster Biological Technology, Wuhan, China) for 30 min, the sections were stained with diaminobenzidine and photographed under a microscope. Four random and nonoverlapping positively stained microscopic fields at 400× magnification were examined in each section. The protein expression levels in each section were measured with integral optical density values (IOD) (IOD = sum of four discontinuous visual fields/4) measured with Image-Pro Plus 6.0 software (Media Cybernetics Inc., Maryland, USA).

Statistical analysis

All in vitro experiments were repeated three times. Two-tailed unpaired Student’s t-tests and one-way ANOVA (analysis of variance) were used to evaluate the differences between the two groups. GraphPad Prism 6 software (San Diego, CA) was used for the statistical analysis. All quantitative data were presented as mean ± standard error of mean. P<0.05 was considered statistically significant.

Results

Crocin inhibited viability and invasion capacity of SiHa cells

To test the effects of crocin on SiHa cells, cells were incubated with 0.06, 0.13, 0.25, 0.5, 1, 2, 4, 8 and 16 mM of crocin in 100 µL of medium for 24 hours. The viability of SiHa cells were dose-dependently reduced with crocin, with 2, 4, 6 and 8 mM significantly reducing cell viability (). In later experiments, 0, 1, 2 and 4 mM concentrations of crocin were established to show its underlying mechanism. The invasive cells tested with a transwell migration assay showed a significant reduction in the 2 mM group, and even fewer in 4 mM group (). The results demonstrate the inhibition of cell viability and invasion of SiHa cells treated with crocin.

Figure 1

Cell viability and invasion of SiHa cells treated with crocin. (A) SiHa cells were treated with indicated concentrations of crocin for 24 hours and viability was tested using a CCK-8 assay; (B) invasive SiHa cells treated with 0, 1, 2 and 4 mM of crocin for 24 hours and tested with a Matrigel-enabled transwell migration assay, stained with crystal violet and observed under 400× scope; (C) the invasive cells were counted. *, P<0.05 versus control with t-test.

Crocin promoted apoptosis of SiHa cells

Apoptosis is a common downstream mechanism of most anticancer therapeutics. In crocin treated SiHa cells, apoptosis was significantly induced by 2 and 4 mM of crocin (). The induced apoptosis was further validated with the increased ratio of cleaved caspase-3/caspase-3 and cleaved caspase-9/caspase-9 (). The results indicated that apoptosis was also the downstream mechanism of crocin in the suppression of SiHa cells.

Figure 2

Apoptosis of SiHa cells treated with crocin. SiHa cells were treated with 0, 1, 2 and 4 mM of crocin for 24 hours. (A) The apoptotic SiHa cells were assessed using flow cytometry; (B) the apoptotic cell counts are shown in bar graphs; (C) markers of apoptosis were measured with western blotting; (D) the ratio of cleaved caspase-3/caspase-3 and cleaved caspase-9/caspase-9 were estimated with Image J. *, P<0.05 versus control with t-test.

Crocin enhanced autophagy of SiHa cells

The ratio of LC3II/I, Beclin1 and ATG7 were all markedly increased after 2 and 4 mM of crocin treatment (). The induced autophagy was also validated by the presence of increased LC3 puncta positive cells after 2 and 4 mM of crocin treatment (). These results suggest that autophagy was induced dose-dependently after crocin exposure.

Figure 3

Autophagy of SiHa cells treated with crocin. SiHa cells were treated with 0, 1, 2 and 4 mM of crocin for 24 hours. (A) Expression of autophagy marker proteins were measured with western blotting; (B) the relative expression of LIC II/I, Beclin1 and ATG7 were estimated with Image J; (C) LC3 puncta in SiHa cells were visualized with immunofluorescence and observed under 400× scope, green: LC3 puncta, blue: nucleus; (D) LC3 puncta per cell were evaluated with Image Pro Plus. *, P<0.05 versus control with t-test.

Crocin inactivated AMPK/MTOR

AMPK, AKT and mTOR are implicated in the regulation of autophagy and apoptosis in crocin treated cells (12). As shown in , the ratio of p-AMPK/AMPK and p-mTOR/mTOR were inhibited dose-dependently, while p-AKT/AKT increased. These results indicate that AMPK and mTOR signaling were potentially involved in the mechanism of action of crocin in suppressing SiHa cell proliferation.

Figure 4

AMPK, AKT and mTOR expression in SiHa cells treated with crocin. SiHa cells were treated with 0, 1, 2 and 4 mM of crocin for 24 hours. (A) Protein expression of AMPK, p-AMPK, AKT, p-AKT, mTOR and p-mTOR were measured with western blotting; (B) the protein expression profiles were measured with Inage J. *, P<0.05 versus control with t-test.

Crocin suppressed tumor progression in vivo

In SiHa cell-bearing mice, 50mg/kg/d of crocin significantly reduced tumor formation (). The tumor volumes in the crocin group were significantly smaller than the control group (). Proliferation and metastases were inhibited with crocin (), as seen through increased caspase-3 () and reduced VEGF () in treated tumors. Autophagy in the tumors was assessed using western blotting (), and demonstrated that the ratio of LC3II/I was significantly elevated in tumors of crocin treated mice ().

Figure 5

In vivo effects of crocin. SiHa cervical cancer cells were inoculated in female BALB/c mice. The mice were injected with crocin (50 mg/kg/d) or saline for 28 days. (A) The tumors were imaged; (B) the tumors were weighed and compared; (C) immunohistochemical staining of the tumors observed under 200× scope showing caspase-3 and VEGF, violet: cell nucleus, yellow: Caspase-3 or VEGF positive signal. Caspase-3 (D) and VEGF (E) positive cells were counted; (F) LC3 expression in tumors; (G) the relative expression of LC3II/I was measured with Image J. *, P<0.05 versus control with t-test.

Discussion

Persistent viral infection of the high-risk HPV subtype is the main cause of cervical cancer worldwide. The risk for cervical cancer remains high in certain countries, despite the increasing availability of vaccination (13). Chemotherapy for late stage cervical cancer mainly includes carboplatin/paclitaxel or topotecan/paclitaxel combined with bevacizumab (14,15). Development of novel therapeutic strategies is still required, as current treatment options remain limited. In the present study, we showed that crocin inhibited the progression of cervical cancer in vitro and in vivo, as indicated by the inhibition of proliferation and invasion, and the promotion of autophagy and apoptosis in SiHa cells and in xenograft mice. These effects were at least partly the result of inactivated AMPK/mTOR pathway, supporting the value of autophagy promoting effects in treating cervical cancer. We suggest that crocin is worthy of further study to combat cervical cancer.

Crocin has been implicated in tumor suppression across multiple cancers, through several complex pathways and mechanisms (16). For example, crocin exerts anti-tumor effects through the activation of p53 and Bax while inactivating Bcl-2 in gastric cancer and lung cancer (17,18), inactivating NF-κB and inflammation in colorectal cancer (19), and inhibiting histone deacetylase 2, Wnt/β-catenin and CD34 in breast cancer (20-22). Molecular docking has predicted several targets for crocin, including telomeric DNA (23), coronavirus (nCoV-2019) main protease (24), human tyrosinase (25), human serum albumin (26), glucagon-like peptide-1 (GLP-1) receptor (27), catalase (28), TLR4 and TGF-βR1 (29). Most of these predicted targets have been validated in specific cells. The many predicted targets partly explain the complex mechanism of action for crocin. On the other hand, some of these targets highlight the potential for adverse effects and interactions with other therapeutics that may limit the development and application of crocin, such as raising blood glucose, competing receptors, or changing the in vivo distribution of drugs.

Currently, the mechanism of action for crocin in cervical cancer mainly includes the induction of apoptosis and the inhibition of proliferation (8). Crocin also suppressed spindle microtubule dynamics and reduced the cell viability of HeLa cells without significantly increasing cellular ROS (30,31). In the present study, we also demonstrated a dose-dependent inhibition of cell proliferation. Additionally, invasive cells were reduced after crocin exposure, and apoptosis and autophagy were induced after crocin treatment. These results suggest that autophagy induced apoptosis in crocin treated SiHa cells. The AMPK, AKT and mTOR pathways are implicated in the regulation of autophagy and apoptosis in crocin treated cells in other tumors (12). In the present study, AMPK and mTOR were inactivated while PI3K was activated with crocin treatment. These results suggest that induced autophagy was a result of inhibited AMPK rather than PI3K.

Using a relatively high concentration, Jiang et al. showed that 125 mg/L of crocin inhibited the proliferation of HeLa cells in vitro; and 120 mg/kg of crocin in male albino rats decreased alanine transaminase (ALT), aspartate transaminase (AST), lactate dehydrogenase (LDH), alkaline phosphatase (ALP), blood urea nitrogen (BUN), creatinine, bilirubin, albumin and total protein, while increasing glucose, cholesterol, thyroglobulin (TG), and glutathione (GSH) (32). Based on these results, they argued that the adverse effects of crocin might limit its clinical application. However, crocin has long been utilized as a food colorant and additive in the food industry worldwide, which strongly supports its safety profile (33). On the other hand, less protein/peptides and more glucose or TG in serum may be of benefit in combating tumors, as the protein supply of tumors can be limited and the immune system can be activated. In this study, we observed no significant adverse effects in mice. Crocin administration significantly reduced tumor growth, and promoted autophagy and apoptosis. These results support the efficacy and safety of crocin for cancer treatment.

There are limitations to this study. There are many reported targets of crocin, and the mechanism of action for crocin in cervical cancer is complicated, but only one aspect was investigated in the current study. The complexity of crocin also raises concerns about potential adverse effects and possible interactions with other therapeutics, which remain largely unexplored.

In conclusion, we showed that crocin inhibited proliferation and invasion, and promoted autophagy and apoptosis of SiHa cells and in xenograft mice. We propose that the anti-tumor effects of crocin was a result of induced autophagy through AMPK and mTOR inhibition but not PI3K. Also, the results suggest that crocin could be a potential prodrug for cervical cancer treatment.

The article’s supplementary files as